Efforts to eradicate malaria in some countries may be counter-productive, an international team of researchers suggest. In the Lancet, they suggest some countries, particularly in sub-Saharan Africa, may be better pursing a policy of controlling the disease. They also criticise the World Health Organization (WHO) for not providing adequate direction. But a WHO spokesman said beating malaria must remain the ultimate goal. 'Noble' goal The Lancet looks at the feasibility of eradicating malaria from the map, in the same way smallpox was conquered. As the report points out, the Bill and Melinda Gates Foundation set the world such a target in 2007, an aim which was then endorsed by the WHO's Director-General Margaret Chan. The Lancet concludes such a goal, while noble, "could lead to dangerous swings in funding and political commitment, in malaria and elsewhere". And the WHO is accused of failing "to rise to their responsibilities to give the malaria community essential direction". The series of articles instead urges a pragmatic approach in which efforts and resources are concentrated on shrinking the global area where malaria still prevails. It suggests some countries, particularly in sub-Saharan Africa, may be better pursuing a policy of controlling the disease rather than one of eradication. The report's authors include Professor Richard Feacham of University of California's Global Health Group and researchers from the Clinton Health Access Initiative. Saving lives In an editorial accompanying the series, the Lancet's editor-in-chief Dr Richard Horton and executive editor Dr Pamela Das, argue control may save more lives. "If existing control efforts were indeed scaled up, by 2015, 1.14 million children's lives could be saved in sub-Saharan Africa alone. This finding is important. The quest for elimination must not distract existing good malaria control work," they write. They also conclude that "malaria will only be truly eradicable when an effective vaccine is fully available". Responding to the report in a statement, Robert Newman, director of the WHO's Global Malaria Programme, said the ultimate goal had to be eradication "WHO has always supported - and will always continue to support - endemic countries in their efforts to control and eliminate malaria," he writes. "It is entirely feasible to eliminate malaria from countries and regions where the intensity of transmission is low to moderate, and where health systems are strong. "Eliminating malaria from countries where the intensity of transmission is high and stable, such as in tropical Africa, will require more potent tools and stronger health systems than are available today." Shrinking map Malaria is caused by five species of a parasite that can be carried from human to human by mosquitoes. Over the last 150 years, the portion of the world where malaria is still endemic has shrunk, but the disease is still endemic in 99 countries. However 32 of these countries, most of them on the edges of the endemic zone, are attempting to eradicate the disease, while the rest are trying to reduce infections and deaths though control measures. But switching from a policy of controlling the disease to one of eradication brings with it problems and risks, according to the report. The authors point out that malaria and mosquitoes do not respect national borders and that both parasite and insect may develop resistance to existing drugs. They also warn switching funds from control to eradication may negatively impact upon measures which have been shown to reduce infection and mortality. The picture is further complicated by the fact that countries are dealing with two main malaria parasite species - Plasmodium falciparum and Plasmodium vivax. While there is more research available on the former and more drugs available to combat it, most of the countries trying to eliminate malaria currently are largely threatened by the latter species P vivax. A combination of drugs from the artemisinin family are generally used to tackle P falciparum while primaquine is the only registered drug available to combat P vivax. The Gates Foundation was unavailable for comment. Source: BBC